A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC).
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Aflibercept (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 06 Oct 2015 Status changed from active, no longer recruiting to completed as per results published in JCO 2014
- 06 Jun 2012 Planned end date changed from 1 Jul 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 06 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.